Acute Studies on the Glycemic Index After Intake of Different Sorts of Barley in Subjects With Type 2 Diabetes

Plain-language summary

This study examines the short-term effects of consuming different types of barley (including gene-modified high-amylose barley) on the blood sugar response (glycemic index) in people with type 2 diabetes. It enrolled people diagnosed with type 2 diabetes per standard Danish guidelines with an HbA1c between 48-78 mmol/l. The study was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University of Aarhus

Intervention

100% wheat, 50% nude barley and 50% wheat, 75% nude barley and 25% wheat, 50% gene-modified high-amylose barley and 50% wheat

Start date

2/8/2021

Estimated completion

10/29/2021

Countries

Denmark

Related genes

Locations

• Aarhus, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Type 2 diabetes (T2D) defined by standard Danish guidelines.
* HbA1c between 48-78 mmol/l.
* Treatment with drugs for hypertension and high cholesterol is allowed if the treatment dose is stable and does not demand changes during the study period.
* Participants are encouraged to maintain their present psychical activity level and their smoking and alcohol habits.

Exclusion Criteria:

* Type 1 diabetes
* Insulin demanding T2D
* Use of weekly administrated GLP-1 antagonist (e.g. ozempic, trulicity or byetta)
* Use of acarbose
* Significant cardiovascular, kidney, liver or endocrine comorbidity
* Significant psychiatric history
* Treatment with steroids
* Alcohol or drug abuse
* Pregnancy or breastfeeding
* Legally incompetent